These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37858275)

  • 1. Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
    O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
    Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
    Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
    Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
    Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
    BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.
    Marchesi I; Sanna L; Fais M; Fiorentino FP; Giordano A; Bagella L
    J Cell Physiol; 2018 Mar; 233(3):2360-2365. PubMed ID: 28722764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
    Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
    Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of human rhabdomyosarcoma cell lines to retinoic acid: relationship with induction of differentiation and retinoic acid sensitivity.
    Ricaud S; Vernus B; Bonnieu A
    Exp Cell Res; 2005 Dec; 311(2):192-204. PubMed ID: 16236281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
    Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
    Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
    Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
    Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells
    Al-Ghabkari A; Narendran A
    Cancer Biol Ther; 2021 Apr; 22(4):333-344. PubMed ID: 33978549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation.
    Marchesi I; Fiorentino FP; Rizzolio F; Giordano A; Bagella L
    Cell Cycle; 2012 Oct; 11(20):3828-36. PubMed ID: 22983009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis.
    Casciello F; Kelly GM; Ramarao-Milne P; Kamal N; Stewart TA; Mukhopadhyay P; Kazakoff SH; Miranda M; Kim D; Davis FM; Hayward NK; Vertino PM; Waddell N; Gannon F; Lee JS
    Cancer Res; 2022 Apr; 82(7):1208-1221. PubMed ID: 35149587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide induces the differentiation of retinoic acid-resistant neuroblastoma cells via upregulation of HoxC9.
    Li C; Feng C; Chen Y; Wu P; Li P; Xiong X; Peng X; Wang Z; Li Y
    Adv Clin Exp Med; 2022 Aug; 31(8):903-911. PubMed ID: 35467087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
    Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
    Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
    Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
    Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
    Benoit YD; Laursen KB; Witherspoon MS; Lipkin SM; Gudas LJ
    J Cell Physiol; 2013 Apr; 228(4):764-72. PubMed ID: 23001792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines.
    Schmidt A; Behrendt L; Eybe J; Warmann SW; Schleicher S; Fuchs J; Schmid E
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis.
    Jiang Y; Xiang C; Zhong F; Zhang Y; Wang L; Zhao Y; Wang J; Ding C; Jin L; He F; Wang H
    Theranostics; 2021; 11(1):361-378. PubMed ID: 33391480
    [No Abstract]   [Full Text] [Related]  

  • 19. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
    Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
    Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.